{
    "SPADE_UN_12110": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_12110",
            "Peptide Name": "SP9 (De Novo Synthesis)",
            "Source": "synthetic construct",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "KVWSRLRKIFSTR",
            "Sequence Length": 13,
            "UniProt Entry": "No entry found",
            "Protein Existence": "Synthetic form",
            "Biological Activity": [
                "Antimicrobial",
                "Antibacterial",
                "Anti-Gram-"
            ],
            "Target Organism": "[Ref.31163671] Gram-negative bacteria:Escherichia coli ATCC 25922 (MIC=6.25–12.5 µg/mL)",
            "Hemolytic Activity": "[Ref.31163671] 10% hemolysis at 50–100 μg/mL against human blood cells.",
            "Cytotoxicity": "[Ref.31163671] The cell viability of Hepa 1-6 induced by SP9 is 104.7%, 110.8%, 108.8%, 108.8%, 97.3% and 79.1% at peptide concentrations of 3.125, 6.25, 12.5, 25, 50 and 100 μg/mL.",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Linear",
            "N-terminal Modification": "Free",
            "C-terminal Modification": "Amidation",
            "Stereochemistry": "L",
            "Structure Description": "Not found",
            "Formula": "C77H129N25O17",
            "Mass": 1677.01,
            "PI": 12.0,
            "Net Charge": 5,
            "Hydrophobicity": -0.71,
            "Half Life": "Mammalian:1.3 hourYeast:3 minE.coli:2 min",
            "Function": "Antibacterial activity against Gram-negative bacteria.",
            "Literature": [
                {
                    "Title": "De Novo Design and In Vitro Testing of Antimicrobial Peptides against Gram-Negative Bacteria.",
                    "Pubmed ID": "31163671",
                    "Reference": "Pharmaceuticals (Basel). 2019 Jun 3;12(2). pii E82. doi 10.3390/ph12020082.",
                    "Author": "Boris Vishnepolsky, George Zaalishvili, Margarita Karapetian, Tornike Nasrashvili, Nato Kuljanishvili, Andrei Gabrielian, Alex Rosenthal, Darrell E. Hurt, Michael Tartakovsky, Maya Grigolava and Malak Pirtskhalava",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=31163671"
                },
                {
                    "Title": "De novo Design and In Vitro Testing of Antimicrobial Peptides against Gram-negative Bacteria",
                    "Pubmed ID": "",
                    "Author": "Vishnepolsky B, Zaalishvili G, Karapetian M, nasrashvili T, Kuljanishvili n, Gabrielian A, Rosenthal"
                }
            ],
            "Frequent Amino Acids": "RKS",
            "Absent Amino Acids": "ACDEGHMNOPQUY",
            "Basic Residues": 5,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 5,
            "Polar Residues": 9,
            "Positive Residues": 5,
            "Negative Residues": 0,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_18669",
                    "Similarity": 1.0,
                    "Sequence": "FSTRF"
                },
                {
                    "SPADE_ID": "SPADE_N_08522",
                    "Similarity": 0.8,
                    "Sequence": "FLGALFKVWSK"
                },
                {
                    "SPADE_ID": "SPADE_UN_04121",
                    "Similarity": 0.8,
                    "Sequence": "KIKSALKTLKSFKKTAAHTLFKVWSS"
                }
            ]
        }
    }
}